12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Company News  |  Other News

Taro pharmaceuticals news

Taro sent a letter to shareholder IsZo Capital Management L.P. rejecting IsZo's claim that Taro reported 3Q12 results that were "suspiciously inconsistent" with prescription and sales data from information services provider IMS. IsZo said that based on IMS data, Taro should have reported 3Q12 sales of $176.4 million. Taro instead reported 3Q12...

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >